#### Number of authors per country

Total worldwide: 55933



Country	Experts			
United States	14071			
Japan	5137			
China	3494			
Italy	3026			
Germany	2351			
United Kingdom	2213			
Spain	2116			
India	1853			
France	1822			
Iran	1630			
Canada	1278			
Taiwan	1168			
Brazil	1122			



### Number of Trial Investigators per country

Total worldwide: 3005



Country	Experts
United States	805
France	152
Spain	144
United Kingdom	138
Italy	134
Egypt	125
Japan	105
India	104
Brazil	94
Denmark	90
Germany	87
Netherlands	79
Canada	75




# Main topics in 2024/2025 publications



MASH is clearly a multi organ disease associated with diabetes and obesity




# **Medical Publications**





# **Clinical Studies**





#### Most popular publications

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.

Hepatocellular carcinoma.

Steatotic liver disease.

Title

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.	N Engl J Med	9	96.2	2024	10.1056/NEJMoa2401755
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.	N Engl J Med	18	96.2	2024	10.1056/NEJMoa2401943
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.	N Engl J Med	205	96.2	2024	10.1056/NEJMoa2309000
Diagnosis and Management of Cirrhosis and Its Complications: A Review.	JAMA	72	63.5	2023	10.1001/jama.2023.5997
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.	Nat Med	78	58.7	2023	10.1038/s41591-023-02603-1

Journal

Lancet

N Engl J

Lancet

Med

Citations SLR~ Year

168.9

158.5

98.4

2022

2022

851

337

6

DOL

10.1016/S0140-6736(22)01200-

10.1056/NEJMoa2210645

2024 10.1016/S0140-6736(24)01811-



## Pharma industry - Up to 100 companies

Corcept Therapeutics (United States)

Sponsor		Total Trials					
√ AstraZeneca				15			
Phase	Recruiting	Active	Terminated	Withdrawed	Count		
Phase 2	0	1	2	0	3		
Phase 1/Phase 2	1	0	0	0	1		
Phase 1	0	1	9	0	10		
N/A	1	0	0	0	1		
> Novo Nordisk				11			
> Pfizer				8			
> Boehringer Ingelheim				8			
> Zydus Pharmaceuticals USA Inc				6			




6

## **Top 20 Key experts**

Expert	Organization	Specialty	Country	SLR	Articles	1st Author	Last Author	Studies	PI
Rohit Loomba	Advocate Children's Hospital	gastroenterology, hepatology	United States	2393.94	247	17	90	27	3
Arun J Sanyal	Virginia Commonwealth University Medical Center	gastroenterology, hepatology	United States	2115.99	202	21	56	27	6
Vlad Ratziu	Pitié-Salpêtrière Hospital	hepatology	France	1408.41	102	13	10	20	2
Zobair M Younossi	Inova Health System	gastroenterology	United States	1111.88	148	44	54	5	0
Sven Francque	Antwerp University Hospital	hepatology	Belgium	964.68	84	10	9	11	2
Eric Lawitz	Texas Liver Institute	gastroenterology, hepatology	United States	750.65	34	3	2	13	0
Kris V Kowdley	Liver Institute Northwest	gastroenterology, hepatology	United States	577.53	37	0	3	9	0
Michael Trauner	Universitätsklinik für Hals-, Nasen- und Ohrenkrankheiten	hepatology	Austria	460.21	54	1	17	3	1
Shiv Kumar Sarin	Institute of Liver and Biliary Sciences	hepatology	India	278.03	37	2	17	5	2
Samuel Klein	Washington University Medical Center	endocrinology	United States	194.02	21	0	2	2	1
Juan P Frias	Biomea Fusion, Inc.	endocrinology	United States	190.67	6	0	0	4	0
Amirhossein Sahebkar	Chitkara University	biochemistry	India	159.76	41	2	33	0	0
Stanislas Pol	Hôpital Cochin	hepatology	France	147.53	8	0	0	2	0
Mitchell L Shiffman	Bon Secours Liver Institute of Richmond	gastroenterology, hepatology	United States	143.66	10	1	0	2	0
Kazuhiko Koike	Kanto Central Hospital	gastroenterology	Japan	133.66	19	0	7	0	0



**Clinical sites and trialists in Europe** 





### Clinical sites and trialists in United States

